Advertisement
Canada markets close in 1 hour 29 minutes

  • S&P/TSX

    21,964.25
    +78.87 (+0.36%)
     

  • S&P 500

    5,102.88
    +54.46 (+1.08%)
     

  • DOW

    38,268.59
    +182.79 (+0.48%)
     

  • CAD/USD

    0.7317
    -0.0006 (-0.09%)
     

  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     

  • Bitcoin CAD

    87,430.93
    -955.43 (-1.08%)
     

  • CMC Crypto 200

    1,334.21
    -62.33 (-4.46%)
     

  • GOLD FUTURES

    2,352.10
    +9.60 (+0.41%)
     

  • RUSSELL 2000

    2,003.87
    +22.75 (+1.15%)
     

  • 10-Yr Bond

    4.6710
    -0.0350 (-0.74%)
     

  • NASDAQ

    15,922.26
    +310.50 (+1.99%)
     

  • VOLATILITY

    15.09
    -0.28 (-1.82%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6836
    +0.0015 (+0.22%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Latest stubborn U.S. inflation reading will bring about more 'wait and see' from the Fed

Stocks in play: Oncolytics Biotech Inc

Baystreet.ca

Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium, which is being held at the Henry B. González Convention Center in San Antonio, Texas through December 10, 2022. Oncolytics Biotech Inc shares T.ONC are trading -$0.05 at $2.35.

Read: